News Focus
News Focus
Replies to #20897 on Biotech Values
icon url

midastouch017

12/21/05 3:28 AM

#20900 RE: DewDiligence #20897

<for one thing, the cultural clash would seem to be astronomical.>

I beg to differ.Actually the guys from the respective
companies have met so often in court, there is a lot
of respect for each other, in spite of what they
officially say in the courtrooms.

<PFE could buy a basket of mid-cap companies such as
AGN and FRX or, if they wanted to go biotech, BIIB and
either AGN or FRX.>

PFE, A market leader by far, cannot go for second best.
I daresay, if PFE seriously considers growing via the
generic venue, it will be TEVA or no generic venue at all.

<they don’t know that well.>

By allowing TEVA to become a semi independent division,
PFE solves this problem entirely.

Once again, JME*HO

Dubi
E*=Extremely





icon url

Biopharm investor

12/21/05 3:34 PM

#20921 RE: DewDiligence #20897

PFE Pipeline

Dew,

"PFE does have one of the best late-stage pipelines in the business"

Not that it matters, but I do not agree with that assessment.

Regards